EP1242050A4 - Stimulation de l'angiogen se par l'utilisation de survivine - Google Patents

Stimulation de l'angiogen se par l'utilisation de survivine

Info

Publication number
EP1242050A4
EP1242050A4 EP00990262A EP00990262A EP1242050A4 EP 1242050 A4 EP1242050 A4 EP 1242050A4 EP 00990262 A EP00990262 A EP 00990262A EP 00990262 A EP00990262 A EP 00990262A EP 1242050 A4 EP1242050 A4 EP 1242050A4
Authority
EP
European Patent Office
Prior art keywords
survivin
angiogenesis
promotion
survivin promotion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00990262A
Other languages
German (de)
English (en)
Other versions
EP1242050A2 (fr
Inventor
Dario C Altieria
William C Sessa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP1242050A2 publication Critical patent/EP1242050A2/fr
Publication of EP1242050A4 publication Critical patent/EP1242050A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
EP00990262A 1999-12-21 2000-12-21 Stimulation de l'angiogen se par l'utilisation de survivine Withdrawn EP1242050A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17299199P 1999-12-21 1999-12-21
US172991P 1999-12-21
PCT/US2000/034663 WO2001046455A2 (fr) 1999-12-21 2000-12-21 Stimulation de l'angiogenèse par l'utilisation de survivine

Publications (2)

Publication Number Publication Date
EP1242050A2 EP1242050A2 (fr) 2002-09-25
EP1242050A4 true EP1242050A4 (fr) 2004-05-26

Family

ID=22630045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00990262A Withdrawn EP1242050A4 (fr) 1999-12-21 2000-12-21 Stimulation de l'angiogen se par l'utilisation de survivine

Country Status (6)

Country Link
EP (1) EP1242050A4 (fr)
JP (1) JP2003529554A (fr)
AU (1) AU2730801A (fr)
CA (1) CA2393646A1 (fr)
MX (1) MXPA02006167A (fr)
WO (1) WO2001046455A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2002007732A2 (fr) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Composes efficaces sur le plan pharmaceutique et utilisation associee
WO2003062421A1 (fr) 2002-01-17 2003-07-31 The University Of British Columbia Oligonucleotides antisens bispecifiques qui inhibent l'igfbp-2 et l'igfbp-5 et procedes d'utilisation associes
ATE478142T1 (de) 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
AU2004233043A1 (en) * 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
WO2005094899A1 (fr) 2004-04-02 2005-10-13 The University Of British Columbia Traitement de cancers par un antisens anti-clusterine
NZ555645A (en) 2004-11-09 2009-08-28 Santaris Pharma As LNA oligonucleotides and the treatment of cancer
WO2009043104A1 (fr) * 2007-10-04 2009-04-09 Bionomics Limited Marqueurs de cellules endothéliales et leurs utilisations
FR2932086A1 (fr) * 2008-06-06 2009-12-11 Lvmh Rech Methode de soin cosmetique anti-age par stimulation de l'expression de la survivine
ES2683831T3 (es) 2013-03-15 2018-09-28 Iris International, Inc. Método y composición para la tinción y el procesamiento de muestras
US10167340B2 (en) 2015-09-04 2019-01-01 Health Research, Inc. Anti-survivin antibodies for cancer therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUJIKAWA KOSHI ET AL: "Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells", EXPERIMENTAL CELL RESEARCH, vol. 253, no. 2, 15 December 1999 (1999-12-15), pages 663 - 672, XP002275040, ISSN: 0014-4827 *
FUJIO Y ET AL: "Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 23, April 1999 (1999-04-01), pages 16349 - 16354, XP002136061, ISSN: 0021-9258 *
LI F ET AL: "PLEIOTROPIC CELL-DIVISION DEFECTS AND APOPTOSIS INDUCED BY INTERFERENCE WITH SURVIVIN FUNCTION", NATURE CELL BIOLOGY, MACMILLAN PUBLISHERS, GB, vol. 1, December 1999 (1999-12-01), pages 461 - 466, XP001034788, ISSN: 1465-7392 *
See also references of WO0146455A3 *

Also Published As

Publication number Publication date
EP1242050A2 (fr) 2002-09-25
CA2393646A1 (fr) 2001-06-28
AU2730801A (en) 2001-07-03
JP2003529554A (ja) 2003-10-07
WO2001046455A2 (fr) 2001-06-28
WO2001046455A3 (fr) 2002-05-10
MXPA02006167A (es) 2004-02-26

Similar Documents

Publication Publication Date Title
EP0984692A4 (fr) Nouveaux inhibiteurs d'angiogenese
EP1017682A4 (fr) Nouveaux inhibiteurs de l'angiogenese
EP1109555A4 (fr) Nouveaux inhibiteurs d'angiogenese
EP1097147A4 (fr) Nouveaux inhibiteurs de l'angiogenese
EP1242050A4 (fr) Stimulation de l'angiogen se par l'utilisation de survivine
EG23070A (en) Novel propargylether derivatives
AU3771000A (en) Method of promoting angiogenesis
IL148031A0 (en) Torsemide polymorphs
HU9902628D0 (en) Angiogenesis inhibiting compounds
HUP0204217A3 (en) Novel a-500359 derivatives
GB9920919D0 (en) Novel compound
AU5252900A (en) Novel isocoumarin derivatives inhibiting angiogenesis
EP1209240A4 (fr) Nouveau compose appele f-15078
GB9919730D0 (en) Bonding of concrete parts
CA85805S (en) Walker
CA85813S (en) Walker
TW411822U (en) Novel structure of offering libations
GB9909300D0 (en) Angiogenesis detection
TW424505U (en) Novel structure of hoop
TW391300U (en) Improvement of blowing-nozzle type balloon
GB9914659D0 (en) Easy walker
TW399438U (en) Improved structure of bedhead
GB9914171D0 (en) Dinosaur bracket
TW410751U (en) Structure of glue can
TW394123U (en) Structure of emery-roller

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020618

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 31/713 B

Ipc: 7A 61K 38/17 B

Ipc: 7C 12N 15/12 B

Ipc: 7C 07K 14/515 B

Ipc: 7A 61K 31/711 B

Ipc: 7C 07K 14/47 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040416

17Q First examination report despatched

Effective date: 20050322

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051002